Spotlight on ASCO Recap

Dear MOASC Members,

Thank you for joining us at the MOASC and UCI’s “Spotlight on ASCO,” held Saturday, July 16, 2016, at the Hyatt Regency in Huntington Beach.

Below is a synopsis of the event:

  • Breakfast and Exhibit Hall with Program Sponsors
  • Welcome message from Jason Zell, DO, MPH Associate Professor, Depts. Of Medicine & Epidemiology School of Medicine University of California, Irvine
  • John Fruehauf, MD, PhD Director Clinical Pharmacology and Developmental Therapeutics UC Irvine Comprehensive Cancer Center, who spoke on Genitourinary, Melanoma.
  • Sai Hong Ignatius Ou, MD PhD UC Irvine School of Medicine discussed Lung Cancer.
  • Samuel Klempner, MD, Director of Precision Medicine The Angeles Clinic and Research Institute presented an Update in Non-Colorectal GI Malignancies.
  • Jason Zell, DO, MPHAssociate Professor, Depts. Of Medicine & Epidemiology School of Medicine University of California, Irvine presented GI-Colorectal Cancer Abstracts.
  • Chaitali Nangia, MD UC Irvine School of Medicine spoke on Breast Cancer Updates.
    Kanwar Kahlon, M.D. Assistant Clinical Professor, Department of Medicine UC Irvine School of Medicine discussed Multiple Myeloma.
  • Networking Lunch and Raffle. The raffle winners were: Dr. Bharadwaj, Pacific Cancer Medical Center; Dr. Moss; Dr. Ou (UCI); and Dr. Sapra.

If you were unable to attend, you can view the entire program here: Spotlight on ASCO

If you would like copies of the presentation slides, please email [email protected]

MOASC would like to thank
Alexion, Amgen, American Regent, Astrazeneca, Eli Lilly, Gilead Science, Ipsen Biopharmaceuticals, Johnson and Johnson, McKesson, Medivation, Merck, Phamacyclics, Takeda, Teva for their sponsorship of this meeting.

MOASC and ANCO have written a letter to California state senator Ed Hernandez, to OPPOSE SB 1010 as we believe it will put patients’ access to medicine at risk. Specifically, the requirement to provide a 30-day notice of a price increase on an existing drug will lead to stockpiling or hoarding of needed treatments for patients.  Plans would be required to report on the percentage of the premium attributable to prescription drugs administered in a doctor’s office that are covered under the medical benefit as separate from the pharmacy benefit. For more information click here.

MOASC is pleased to sponsor the Partnership to Fight Chronic Disease briefing taking place in Sacramento on August 2.  5% of people currently account for 50% of health care spending in California. The fight for health in California could save 106,900 lives annually with better treatment and prevention. For more information click here.

Noridian/JEMAC has posted the following updates to its website.*Monthly Revalidation due dates continue. July 31, 2016 is the next due date. Providers missing the May 31, 2016 revalidation will soon be deactivated, while those missing the June 30, 2016 due date will be placed into a Pend Status. For more information click here.

Just seven states achieved a passing grade for making usable healthcare price information available to consumers. A new study finds that the other 43 states failed at price transparency because they didn’t collect claims data from all payers or they failed to make the data accessible to the public through a website. For more information click here.

Ahead of the release of its much-anticipated star ratings for overall hospital quality, CMS published data showing how those star ratings are distributed according to hospital characteristics, such as size and status. The agency said it planned to post overall hospital star ratings “shortly” on its Hospital Compare website. For more information click here.

The FDA is accepting comments through August 2 on “Labeling for Biosimilar Products” draft guidance released by the FDA in March 2016. The labeling will be used by providers and patients. Here is an opportunity to provide the FDA with your input. Additional organizations comments are listed on the FDA Registrar where comments are submitted. For more information click here.

To view the complete California Oncology Weekly Newsletter, click on the date below.

July 26, 2016

CMA’s Practice Resources (July 2016) and features articles entitled: CMA publishes guide on new provider directory accuracy law; Updated payor profiles now available; United Healthcare extended clinical data submission deadline to Sept 2; DMHC IMR/complaint webinar now available; CMA medical legal library updated for 2016; California Insurance Commissioner urges DOJ to block Anthem/Cigna merger; Have you registered for CURES?; Medi-Cal to reimburse providers for advanced care planning; The Coding Corner: How coding guidelines define new vs. established patients. For more information click here.

Noridian/JEMAC reports that only 19% of physicians have responded to the most recent revalidation notices. If you do not know when you are up for revalidation, you can look up your revalidation date through the CMS look-up too. For more information click here.

Ballot measure to provide new funding for Medi-Cal has officially qualified for the November 2016 ballot. The ballot initiative will maintain the taxes on the wealthiest Californians to prevent billions in cuts to education and other vital services The California Secretary of State announced that the initiative could move forward as enough valid signatures were submitted and verified. For more information click here.

MOASC and ANCO are interested to know of their member practices’ receipt of the CVS/Caremark communiqué regarding “In-office Dispensing.” Physicians in several states, including California, are currently experiencing issues with this. Apparently, CMS tacitly supports the CVS/Caremark interpretation that Medicare Advantage Part D drug dispensing should be only allowed for pharmacy networks, and that physician practices and cancer centers do not qualify. For more information click here.

MS has released the proposed CY2017 Medicare Physician Fee Schedule (MPFS) and the proposed CY2017 Hospital Outpatient Prospective Payment System (HOPPS) LEARN WHAT’S IN STORE FOR RADIATION AND MEDICAL ONCOLOGY IN 2017. Join industry experts for two free pre-recorded webinars that will summarize the Proposed Rules changes. For more information click here.

The FDA is accepting comments through August 2 on “Labeling for Biosimilar Products” draft guidance released by the FDA in March 2016.  The labeling will be used by providers and patients. Here is an opportunity to provide the FDA with your input. Additional organizations comments are listed on the FDA Registrar where comments are submitted. For more information click here.

To view the complete California Oncology Weekly Newsletter, click on the date below.

July 19, 2016

MOASC has co-sponsored an event, with Congressman David G. Valadao, the Partnership for Prescription Assistance (PPA) and several local community partners, to host a workshop where families who are unable to afford their prescriptions can determine if they qualify for financial assistance. For more information click here.

Noridian/JEMAC’s MAC Satisfaction Indicator Survey is now available online for providers to complete. This Survey should only take about 10 minutes to complete and helps Noridian/JEMAC understand how to better service its providers. For more information click here.

Stem Cell Transplantation for Multiple Myeloma, Myelofibrosis, and Sickle Cell Disease, and Myelodysplastic Syndromes – Revised CR9620.  Change Request (CR) 9620, from which this article was developed, notifies providers that effective for claims with dates of service on and after January 27, 2016, for the use of allogeneic Hematopoietic Stem Cell Transplantation. For more information click here.

The United States Food and Drug Administration has finalized the Individual Patient Expanded Access Application, a simplified form to make the process easier for physicians to request investigational drugs for their patients–including cancer drugs and treatments under development. For more information click here.

CMS has released the proposed 2017 Medicare Physician Fee Schedule.  CMS estimates that in CY2017 reimbursement for the hematology/oncology specialty is set to increase by 2%, though the actual impact on individual practices will depend on the mix of services provided. For more information click here.

To view the complete California Oncology Weekly Newsletter, click on the date below.

July 12,2016

 

Several California congressional Republicans want the Obama administration to block the state’s request to sell health insurance to undocumented immigrants on the state’s exchange. The move comes after Gov. Jerry Brown signed a bill earlier this month authorizing California to formally request a waiver from the Affordable Care Act provision that bars undocumented immigrants from any of the law’s benefits. For more information click here.

CMA has published a new resource to help physicians comply with the new directory accuracy law that took effect on July 1. Provider Directories is now available online. For more information click here.

Forthcoming Noridian/JEMAC workshops include: * Medicare Secondary Payer Workshop (July 6); * Medicare Secondary Payer Calculation Workshop (July 7); * NCCI and MUEs Workshop (July 12); * Telehealth Services Workshop (July 14). For more information click here.

DHCS/Medi-Cal is following Medicare’s lead by allowing providers to bill for advance care planning discussions with beneficiaries. DHCS/Medi-Cal will accept CPT codes 99497 and 99498. For more information click here.

As part of the $1 billion National Cancer Moonshot effort being run by Vice President Joseph Biden, the FDA appointed Richard Pazdur, M.D. to run the new Oncology Center of Excellence that will coordinate all of the FDA’s clinical efforts in cancer. For more information click here.

CMS has testified before the Senate Finance Committee that the Administration would adjust its plan to reduce Medicare payments for many prescription drugs–but those assurances did not fully allay deep concerns from the Senators. CMS indicated that the Administration would probably go ahead with its proposal in some form and pledged that it would try to prevent any harm to patients. For more information click here.

The American Medical Association (AMA) House of Delegates (HOD) adopted an ASCO-submitted resolution asking CMS to withdraw the Medicare Part B drug reimbursement experiment or alternatively asking Congress to block the experiment from moving forward. For more information click here.

To view the complete California Oncology Weekly Newsletter, click on the date below.

July 5, 2016